Biogened S.A. announced that FDA has approved Biogen and Alkermes' Vumerity (diroximel fumarate) to treat relapsing forms of multiple sclerosis (MS). The approval was based on studies that demonstrated the drug's bioequivalence to Biogen's Tecfidera (dimethyl fumarate), which is also approved to treat relapsing MS, as well as an ongoing phase 3 trial that studied patients with relapsing-remitting MS.